Compare BBBY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BBBY | CTNM |
|---|---|---|
| Founded | 1971 | 2009 |
| Country | United States | United States |
| Employees | 389 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.5M | 550.7M |
| IPO Year | N/A | 2024 |
| Metric | BBBY | CTNM |
|---|---|---|
| Price | $4.91 | $14.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.3M | 459.2K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.26 | $5.08 |
| 52 Week High | $12.65 | $16.91 |
| Indicator | BBBY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Bed Bath & Beyond Inc is an e-commerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering products and services that enable its customers to enhance everyday life through quality, style, and value. The company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites, as well as a blockchain asset portfolio. Its e-commerce platforms, www.bedbathandbeyond.com and www.overstock.com, are targeted at customers seeking various products such as furniture, bedding, area rugs, tabletop and cookware, decor, storage, jewelry, etc, at affordable prices. In addition to products, the company also offers add-on services across platforms, including warranties, shipping insurance, and installation services.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.